Head-to-head · WeighScore
Arc-1 vs Nucific
The verdict
Arc-1 takes it — 56.3/100 to 56.2/100, but only just.
Arc-1 grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Arc-1 offers compounded semaglutide (from $249.99) and compounded tirzepatide (from $299.99) as per-dose purchases, not monthly subscriptions. Nucific is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Arc-1 | Nucific |
|---|---|---|
| WeighScore | 56.3/100 | 56.2/100 |
| Grade | C | C |
| Scorecard rank | #417 | #418 |
| Semaglutide | $200/mo (0.5 mg dose, compounded) | Not disclosed |
| Tirzepatide | $200/mo (2.5 mg dose, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #417 · C
Strengths
- Both compounded semaglutide and tirzepatide available
- Per-dose purchasing — no subscription or membership required
- 25% off plus free shipping promotion
- Broader longevity formulary (rapamycin, NAD+, sermorelin)
- LegitScript Certified badge now displayed on product pages
Where it loses points
- No legal entity name or address disclosed
- State availability not disclosed
- No named clinicians or pharmacy partners
- Per-dose pricing still climbs with dose (semaglutide 2.5mg is $549.99/mo, tirzepatide 7.5mg $399.99/mo)
Graded #418 · C
Strengths
- Founder is named and credentialed: Dr. Amy Lee, MD, triple board-certified in Internal Medicine, Obesity Medicine and Clinical Nutrition
- Cites SURMOUNT-1 properly, naming the trial, the 20.9% average and the Jastreboff NEJM 2022 source
- Discloses that featured patients were compensated for their time
- Labels its NAD+ decline chart as illustrative and not a measurement, with an unusually careful methodology note
- Offers compounded, microdosed and brand-name Ozempic and Zepbound in one catalogue
Where it loses points
- No price is published anywhere; every option is gated behind a three-minute quiz
- The LegitScript badge is a self-hosted image with generic alt text rather than the issued embed, so the certification could not be verified
- A BBB Accredited A+ claim is displayed without a link to the BBB profile
- No state list and no named pharmacy, only licensed U.S. pharmacies
- Before-and-after photographs are used alongside compensated testimonials
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.